Response to motexafin gadolinium and ionizing radiation of experimental rat prostate and lung tumors

International Journal of Radiation Oncology Biology Physics

Volumn 57, Issue 3, 2003, Pages 787-793

  Dehnad, Homan ^a   Kal, Henk B ^a   Stam, Tanja ^a   Gademan, Iris S ^a   Van Moorselaar, R Jeroen A ^a   Van Der Sanden, Boudewijn P J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Gd tex; Motexafin gadolinium; Radiosensitization; Rat tumors

Indexed keywords

IONIZING RADIATION; MAGNETIC RESONANCE IMAGING; MUSCLE; PULMONARY DISEASES; TUMORS;

MICROVESSEL DENSITY;

ONCOLOGY;

GADOLINIUM TEXAPHYRIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL NUCLEUS; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOPLASM; IONIZING RADIATION; LUNG TUMOR; MALE; MICROVASCULATURE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROSTATE TUMOR; RADIATION DOSE FRACTIONATION; RAT; TUMOR GROWTH; TUMOR MODEL; TUMOR VOLUME; VASCULAR ENDOTHELIUM; X RAY DOSE DISTRIBUTION;

EID: 0141727525     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(03)00661-8     Document Type: Article

References (23)

1. Young S.W., Qing F., Harriman A., et al. Gadolinium(III) texaphyrin A tumor selective radiation sensitizer that is detectable by MRI . Proc Natl Acad Sci U S A. 93:1996;6610-6615.
2. Miller R.A., Woodburn K., Fan Q., et al. In vivo animal studies with gadolinium (III) texaphyrin as a radiation enhancer. Int J Radiat Oncol Biol Phys. 45:1999;981-989.
3. Xu S., Zakian K., Thaler H., et al. Effects of motexafin gadolinium on tumor metabolism and radiation sensitivity. Int J Radiat Oncol Biol Phys. 9:2001;1381-1390.
4. Sessler J.L., Tvermoes N.A., Guldi D.M., et al. One-electron reduction and oxidation studies of the radiation sensitizer gadolinium(III) texaphyrin (PCI-0120) and other water soluble metallotexaphyrins. J Phys Chem. 103:1999;787-794.
5. Magda D., Lepp C., Gerasimchuk N., et al. Redox cycling by motexafin gadolinium enhances cellular response to ionizing radiation by forming reactive oxygen species. Int J Radiat Oncol Biol Phys. 51:2001;1025-1036.
6. Woodburn K. Subcellular distribution of the radiation enhancer, motexafin gadolinium (Gd-Tex) using multi-pixel fluorescence microscopy in two cancer cell lines. Proc Am Assoc Cancer Res. 41:2000;834.
7. Woodburn K.W. Intracellular localization of the radiation enhancer Motexafin gadolinium using interferometric Fourier fluorescence microscopy. J Pharmacol Exp Ther. 297:2001;888-894.
8. Rosenthal D.I., Nurenberg P., Becerra C.R., et al. A phase I single-dose trial of gadolinium texaphyrin (Gd-tex), a tumor selective radiation sensitizer detectable by magnetic resonance imaging. Clinical Cancer Res. 5:1999;739-745.
9. Carde P., Timmerman R., Metha M.P., et al. Multicenter phase Ib/II trial of the radiation enhancer motexafin gadolinium in patients with brain metastases. J Clin Oncol. 19:2001;2074-2083.
10. Viala J., Vanel D., Meingan P., et al. Phases IB and II multidose trial of gadolinium texaphyrin, a radiation sensitizer detectable at MR imaging Preliminary results in brain metastases . Radiology. 212:1999;755-759.
11. Bernhard E.J., Mitchell J.B., Deen D., et al. Re-evaluating gadolinium(III) texaphyrin as a radiosensitizing agent. Cancer Res. 60:2000;86-91.
12. Rockwell S., Donnelly E.T., Liu Y., et al. Preliminary studies of the effects of gadolinium texaphyrin on the growth and radiosensitivity of EMT6 cells in vitro. Int J Radiat Oncol Biol Phys. 54:2002;536-541.
13. Dijkman G.A., Van Moorselaar R.J.A., Van Ginckel R., et al. Antitumoral effects of liarozole in androgen-dependent and independent R3327-Dunning prostate adenocarcinomas. J Urol. 151:1994;217-222.
14. Moorselaar RJA van, Hendriks BTh, van Stratum P, et al. Synergistic antitumor effects of rat-gamma-interferon and human tumor necrosis factor alpha against androgen-dependent and -independent rat prostatic tumors. Cancer Res 1991;51:2329-2334.
15. Kal H.B., Meijnders P.J., van Berkel A.H., et al. Response to chemotherapy of non-small cell bronchial rat tumours growing subcutaneously or in the lung. In Vivo. 5:1991;301-306.
16. Kal H.B., van Berkel A.H., Broers J.L., et al. Cytokeratins expressed in experimental rat bronchial carcinomas. Int J Cancer. 53:1993;506-513.
17. Kal H.B., van Berkel A.H., Goedoen H.H. Growth rate, morphology and drug responses of rat lung tumours growing at different sites. Anticancer Res. 14:1994;495-499.
18. 1 Values by SNAPSHOT-FLASH NMR imaging. J Magn Reson. 96:1992;608-612.
19. 1H-MRI of gadolinium-uptake. J Cereb Blood Flow Metab. 20:2000;861-870.
20. Miller R.A., Woodburn K.W., Fan Q., et al. Motexafin gadolinium A redox active drug that enhances the efficacy of bleomycin and doxorubicin . Clin Canc Res. 7:2001;3215-3221.
21. Yeh K.A., Biade S., Lanciano R.M., et al. Polarographic needle electrode measurements of oxygen in rat prostate carcinomas Aaccuracy and reproducibility . Int J Radiat Oncol Biol Phys. 33:1995;111-118.
22. Thorndyke C., Meeker B.E., Thomas G., et al. The radiation sensitivities of R3327-H and R3327-AT rat prostate adenocarcinomas. J Urol. 134:1985;191-198.
23. Young S.W., Sidhu M.K., Qing F., et al. Preclinical evaluation of gadolinium (III) texaphyrin complex. A new paramagnetic contrast agent for magnetic resonance imaging. Invest Radiol. 29:1994;330-338.